RT Journal Article
SR Electronic
T1 Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents.
JF The Journal of Immunology
JO J. Immunol.
FD American Association of Immunologists
SP 4412
OP 4420
VO 157
IS 10
A1 Singh, S
A1 Natarajan, K
A1 Aggarwal, B B
YR 1996
UL http://www.jimmunol.org/content/157/10/4412.abstract
AB Viral replication, immune regulation, and induction of various inflammatory and growth-regulatory genes require activation of a nuclear transcription factor (NF)-kappa B. Agents that can block NF-kappa B activation have potential to block downstream responses mediated through this transcription factor. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a quinone that has been shown to regulate a wide variety of activities that require NF-kappa B activation. In the present study, we examined the effect of capsaicin and its analogue, resiniferatoxin, on the activation of NF-kappa B induced by different agents including TNF. The pretreatment of human myeloid ML-1a cells with capsaicin blocked TNF-mediated activation of NF-kappa B in a dose- and time-dependent manner. Resiniferatoxin was at least eight times as potent as capsaicin in inhibiting NF-kappa B activation. Neither agent by itself activated NF-kappa B or affected the DNA-binding ability of NF-kappa B. Capsaicin also blocked phorbol ester-mediated NF-kappa B activation, but that mediated through okadaic acid was less effective, suggesting there is a difference in the mechanism of activation of NF-kappa B by different agents. Capsaicin treatment of cells also blocked the degradation of I kappa B alpha, and thus the nuclear translocation of the p65 subunit of NF-kappa B, which is essential for NF-kappa B activation. TNF-dependent promoter activity of I kappa B alpha, which contains NF-kappa B binding sites, was also inhibited by capsaicin. Overall our results indicate that capsaicin and its analogue inhibit NF-kappa B activation, and thus could be used as a potential target for drug development.